TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited’s 2025 AGM highlighted significant progress in advancing its Sofra™ technology platform, particularly with the SOF-SKN™ clinical trial in Australia. This advancement enhances the company’s reputation and attracts external stakeholder interest, evidenced by a US patent grant and support from the Victorian government. The company is well-positioned to capitalize on the growing interest in RNA technology and the rise in autoimmune diseases, while maintaining prudent operational spending and exploring funding opportunities.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian clinical-stage biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance mRNA drug safety and develop new oncology drugs. Noxopharm collaborates with leading researchers to advance its drug pipeline.
Average Trading Volume: 111,387
Technical Sentiment Signal: Sell
Current Market Cap: A$26.3M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.